RxDoctor Payments Data

Zaynab Rasheed, MD

Family Medicine · San Antonio, FLNPI 1437688538

Payments from drug & device makers

$1,128in general payments, 2019–2025

Across 49 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$617
  • Regeneron Healthcare Solutions, Inc.$52
  • Xeris Pharmaceuticals, Inc.$47
  • Sanofi-aventis U.S. LLC$45
  • Bayer$41
  • GSK$41
  • plus $285 from 12 others

What the payments were for

  • Food & beverage$1,128100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,128 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$50,468
Medicare patients
181
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$41,860
MounjaroTirzepatide18$25,526
JardianceEmpagliflozin21$25,251
EliquisApixaban15$18,954
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,731
XareltoRivaroxaban11$8,930
Albuterol Sulfate HfaAlbuterol Sulfate54$3,218
Butorphanol Tartrate29$1,451
Atorvastatin Calcium149$1,446
SynthroidLevothyroxine Sodium15$1,223
Levothyroxine Sodium127$1,160
Rosuvastatin Calcium60$944
Gabapentin62$806
Losartan Potassium134$782
Testosterone Cypionate13$754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$617$41,86039 claims
Boehringer IngelheimJardiance$18$25,25121 claims
GSKTrelegy Ellipta$41$9,73114 claims
AbbVieSynthroid$40$1,22315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in San Antonio

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →